GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chiasma Inc (NAS:CHMA) » Definitions » EBITDA per Share

Chiasma (Chiasma) EBITDA per Share : $-1.30 (TTM As of Mar. 2021)


View and export this data going back to 2015. Start your Free Trial

What is Chiasma EBITDA per Share?

Chiasma's EBITDA per Share for the three months ended in Mar. 2021 was $-0.29. Its EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2021 was $-1.30.

During the past 3 years, the average EBITDA per Share Growth Rate was -5.70% per year. During the past 5 years, the average EBITDA per Share Growth Rate was 17.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for Chiasma's EBITDA per Share or its related term are showing as below:

CHMA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -116.4   Med: 9.55   Max: 26
Current: -5.7

During the past 8 years, the highest 3-Year average EBITDA per Share Growth Rate of Chiasma was 26.00% per year. The lowest was -116.40% per year. And the median was 9.55% per year.

CHMA's 3-Year EBITDA Growth Rate is not ranked
in the Biotechnology industry.
Industry Median: 6.25 vs CHMA: -5.70

Chiasma's EBITDA for the three months ended in Mar. 2021 was $-17.99 Mil.

During the past 3 years, the average EBITDA Growth Rate was -36.30% per year. During the past 5 years, the average EBITDA Growth Rate was -5.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 8 years, the highest 3-Year average EBITDA Growth Rate of Chiasma was 15.70% per year. The lowest was -160.40% per year. And the median was -16.20% per year.


Chiasma EBITDA per Share Historical Data

The historical data trend for Chiasma's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chiasma EBITDA per Share Chart

Chiasma Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
EBITDA per Share
Get a 7-Day Free Trial -2.47 -1.11 -1.28 -1.05 -1.31

Chiasma Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.36 -0.48 -0.27 -0.27 -0.29

Chiasma EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Chiasma's EBITDA per Share for the fiscal year that ended in Dec. 2020 is calculated as

EBITDA per Share(A: Dec. 2020 )
=EBITDA/Shares Outstanding (Diluted Average)
=-68.651/52.235
=-1.31

Chiasma's EBITDA per Share for the quarter that ended in Mar. 2021 is calculated as

EBITDA per Share(Q: Mar. 2021 )
=EBITDA/Shares Outstanding (Diluted Average)
=-17.989/62.831
=-0.29

EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chiasma  (NAS:CHMA) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


Chiasma EBITDA per Share Related Terms

Thank you for viewing the detailed overview of Chiasma's EBITDA per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Chiasma (Chiasma) Business Description

Traded in Other Exchanges
N/A
Address
140 Kendrick Street, Building C East, Needham, MA, USA, 02494
Chiasma Inc is a commercial-stage biopharmaceutical company focused on improving the lives of patients who face challenges associated with existing treatments for rare and serious chronic disease. The US Food and Drug Administration, or the FDA, approved MYCAPSSA for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. MYCAPSSA is the first and only oral somatostatin analog, or SSA, approved by the FDA and the first product approved by the FDA utilizing TPE technology. The company is focused on the commercialization of MYCAPSSA for the treatment of patients with acromegaly in the United States and developing and seeking regulatory approval of MYCAPSSA in the European Union.
Executives
Roni Mamluk director CHIASMA, INC., 60WELLS AVENUE, NEWTON MA 02459
David M Stack director THE MEDICINES CO, 8 CAMPUS DRIVE, PARSIPPANY NJ 07054
Raj Kannan director, officer: Chief Executive Officer C/O CHIASMA, INC. 460 TOTTEN POND RD, SUITE 530, WALTHAM MA 02451
John F Thero director C/O AMARIN PHARMA, INC., 1430 ROUTE 6, BEDMINSTER NJ 07921
Bard Geesaman director C/O MPM CAPITAL 450 KENDALL STREET CAMBRIDGE MA 02142
Todd Foley director THE JOHN HANCOCK TOWER, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116
John A Scarlett director C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Scott Minick director C/O BIND THERAPEUTICS, INC. 325 VASSAR ST CAMBRIDGE MA 02139
Anand Varadan officer: EVP, Chief Commerical Officer C/O CHIASMA, INC., 60 WELLS AVENUE, NEWTON MA 02459
Lee Giguere officer: General Counsel C/O CHIASMA, INC. 460 TOTTEN POND ROAD, SUITE 530 WALTHAM MA 02451
William Ludlam officer: See Remarks C/O CHIASMA, INC. 460 TOTTEN POND ROAD, SUITE 530 WALTHAM MA 02451
Drew Enamait officer: VP, Fin & Admin, PAO C/O CHIASMA, INC. 275 WYMAN STREET, SUITE 250 WALTHAM MA 02451
Mark J. Fitzpatrick officer: President 101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142
James R Tobin director C/O CURIS INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Ansbert Gadicke director THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116

Chiasma (Chiasma) Headlines

From GuruFocus